uploads/2018/01/Nektar-Analysts-Reco-1.png

Analysts’ Ratings for Nektar Therapeutics in January 2018

By

Updated

Company overview

San Francisco–based biopharmaceutical company Nektar Therapeutics (NKTR) develops drug candidates that make use of its advanced polymer conjugate technology platforms. These platforms are designed to develop new molecular entities that target known mechanisms of action.

Article continues below advertisement

Analysts’ ratings

Of the nine analysts covering Nektar Therapeutics in January 2018, eight have given it a “buy” rating or higher, and one has recommended “hold.” The mean rating for the stock is 1.7, and its target price is $42.43. Nektar Therapeutics makes up ~1.4% of the iShares Core S&P Small-Cap ETF (IJR).

Peer ratings

In January 2018, of the 26 analysts covering Amgen (AMGN), 11 have given the stock a “buy” rating or higher, while 15 have recommended “hold.” The mean rating for the stock is 2.4, and its target price is $192.14.

Of the 24 analysts covering Bristol-Myers Squibb (BMY), ten have given the stock a “buy” rating or higher, 12 have recommended “hold,” and two have recommended “sell.” The mean rating for the stock is 2.4, and its target price is $64.05.

Of the 24 analysts covering Eli Lilly (LLY), 15 have given the stock a “buy” rating or higher, eight have recommended “hold,” and one has recommended “sell.” The mean rating for the stock is 2.2, and its target price is $92.27. In the next part of this series, we’ll take a look at some of Nektar Therapeutics’ collaboration agreements.

Advertisement

More From Market Realist